Ocular Therapeutix (OCUL) is the lead sponsor of 3 active clinical trials listed on ClinicalTrials.gov[2], including 3 Phase 3[1].
Trial NCT06495918[3] evaluates OTX-TKI in Neovascular Age-related Macular Degeneration with a target enrollment of 825 participants. Trial NCT07235085[4] evaluates Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24 in Non-Proliferative Diabetic Retinopathy with a target enrollment of 930 participants. Trial NCT06223958[5] evaluates OTX-TKI (axitinib implant) in Neovascular Age-Related Macular Degeneration with a target enrollment of 344 participants.
No Form 4 insider filings for OCUL were recorded at the SEC in the past 30 days[6].